- Published on: July 6, 2022
- 17:00
Havana, Jul 6 (Prensa Latina) Studies related to the use of neuroprotective drug NeuralCIM (NeuroEPO) continue in Cuba´s capital by staring off consultations for the classification of patients who will be part of the phase III clinical trial.
